Radiopharmaceuticals: The Billion-Dollar Gold Rush Transforming Cancer Treatment
The Nuclear Medicine Revolution
In the corridors of global pharma, an unprecedented arms race is underway. The coveted weapons aren&
The biopharma royalty market crosses $14 billion in annual deal flow as competition intensifies
The biopharma royalty financing market has emerged as a critical pillar of life sciences funding, with annual transaction volume reaching
The weekly term sheet (36)
The first week of September 2025 saw a flurry of dealmaking in life sciences, with over $11.6 billion in
He Who Controls the Term Sheet Controls the Deal
Dear reader,
A brief desk note from your resident author Sebastian. The kettle is still on, the models still overfit,
Company of the week: OpenAI
Executive Summary
OpenAI's expansion into healthcare represents a significant inflection point in the artificial intelligence industry, driven by
Fund of the week: The Clinique La Prairie Longevity Fund
Fund Launch and Structure
Clinique La Prairie, the Swiss medical spa founded in 1931, launched its Longevity Fund in October
AI Models in Biotechnology: 2025 Market Analysis and Performance Assessment
Executive Summary
The integration of artificial intelligence into biotechnology has reached a critical inflection point in 2025. This comprehensive analysis
Using Generative AI to Create Synthetic Data in Biotech and Pharma
Executive Summary: The $7.8 billion question
The generative AI revolution in biotech synthetic data generation stands at a critical
Yamanaka factors and the reprogramming paradox
The promise of cellular reprogramming through Yamanaka factors represents one of the most profound scientific contradictions in modern medicine: a
The weekly term sheet (35)
Weekly Term Sheet: Pharma & Biotech Deals (August 25–28, 2025)
Key Deal Highlights
Deal Type
Companies
Value
Key Asset/
